Episodic Migraine Study
Episodic migraine is defined has having less than 15 headache days per month, with at least half having migrainous features such as light- and/or sound sensitivity, nausea and/or vomiting. Pharmacotherapy includes either acute treatment (taken at the onset of a migraine to knock it out), or preventive treatment (designed to decrease the total number of headache days per month).
Episodic Migraine Acute Treatment studies
- A migraine patch is a great idea for those who get nauseous or vomit with their migraine, which makes taking pills very difficult. We have a study entitled, “Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine (Zotrip)”.
- Cefaly is a neurostimulator worn on the forehead. It is FDA approved for prevention of migraine, but this study seeks to determine if Cefaly is effective in the acute treatment of migraine.
Episodic Migraine Preventive Treatment studies
CGRP is a major bad guy in migraine generation. We have several studies looking at blocking CGRP with either oral daily medications or with shots of monoclonal antibodies, which are highly specific “smart bombs” designed to stop CGRP in its tracks, but not go elsewhere in the body.
- One CGRP monoclonal antibody study by Alder pharmaceuticals, called, “A Multicenter Assessment of ALD403 in Frequent Episodic Migraine”. It’s an intravenous infusion every three months.
- Another CGRP study is by Teva. “ Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine” involves monthly injections (in the arm) of a monoclonal antibody.
- Lilly pharmaceuticals is evaluating their own CGRP monoclonal antibody. Their study is called, “A Safety Study of LY2951742 in Participants With Migraine, With or Without Aura’. It too is monthly shot in the arm, and subjects are taught to inject themselves at home.
All studies at NEICR are available at no cost, and there is compensation for time and travel. To find out more fill out the form below or call us at 203-914-1903.